EP Patent

EP1198255B1 — Identification of compounds that modify transcriptional responses to hypoxia

Assigned to Dana Farber Cancer Institute Inc · Expires 2008-01-16 · 18y expired

What this patent protects

The invention provides methods for identifying compounds that can be used to modify transcriptional responses to hypoxia, and use of such compounds in therapeutic and diagnostic methods.

USPTO Abstract

The invention provides methods for identifying compounds that can be used to modify transcriptional responses to hypoxia, and use of such compounds in therapeutic and diagnostic methods.

Drugs covered by this patent

Patent Metadata

Patent number
EP1198255B1
Jurisdiction
EP
Classification
Expires
2008-01-16
Drug substance claim
No
Drug product claim
No
Assignee
Dana Farber Cancer Institute Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.